Specnuezhenide suppresses diabetes-induced bone loss by inhibiting RANKL-induced osteoclastogenesis.

Strotmeyer et al . [13] found that among patients with diabetes, approximately 50%–66% showed a decreasing trend in bone mineral density, and approximately 33% were diagnosed with osteoporosis.

also in 47,180 other papers